Hansen Gwenn

Chief Scientific Officer

Hansen Gwenn has filed 9 SEC Form 4 filings (27 transaction rows) across 1 company, with disclosures dating back to 2025. 9 of those filings fall inside the rolling window. Most recent filing: Sep 1, 2026.

On the most recent filing, Hansen Gwenn is listed as Chief Scientific Officer at Nurix Therapeutics, Inc. Inside the rolling window, Hansen Gwenn reported no open-market purchases and 8 open-market sales totaling $631K in NRIX. The largest disclosed transaction in the window is a sale of 4,356 NRIX shares on Aug 5, 2026, worth $109K.

Companies traded

Other insiders at NRIX

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$631K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
NRIXSale$37KSep 1SEC ↗
NRIXSale$109KAug 5SEC ↗
NRIXSale$100KAug 5SEC ↗
NRIXSale$90KJul 30SEC ↗
NRIXSale$108KJun 25SEC ↗
NRIXSale$53KApr 30SEC ↗
NRIXSale$81KJan 30SEC ↗
NRIXSale$52KOct 30SEC ↗
Showing 1–8 of 8
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Hansen Gwenn made?

Hansen Gwenn has filed 9 SEC Form 4 filings (27 transaction rows) across 1 company since 2025.

Which companies does Hansen Gwenn trade?

Hansen Gwenn has filed SEC Form 4 disclosures for 1 company, including NRIX.

When was Hansen Gwenn's most recent SEC Form 4 filing?

Hansen Gwenn's most recent SEC Form 4 filing on Tracefour is dated Sep 1, 2026.

What is Hansen Gwenn's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Hansen Gwenn is listed as Chief Scientific Officer.

What is Hansen Gwenn's total buy and sell value in the current window?

Inside the rolling retention window, Hansen Gwenn bought $0 and sold $631K based on SEC Form 4 filings.

What was Hansen Gwenn's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 4,356 NRIX shares on 2026-08-05, worth $109K, per SEC Form 4 filings.